Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations
Latest Information Update: 11 Aug 2022
At a glance
- Drugs VT 30 (Primary)
- Indications Vascular skin diseases
- Focus Adverse reactions; First in man
- Sponsors Venthera
Most Recent Events
- 01 Aug 2022 Status changed from recruiting to discontinued.
- 10 Jun 2022 According to a BridgeBio Pharma media release, data from this trial are being shared in a virtual presentation to the International Society for the Study of Vascular Anomalies (ISSVA) 2022.
- 10 Jun 2022 Preliminary results from phase 1b study published in the BridgeBio Pharma Media Release.